u/zeynep_weiss

Cosigning on cross-border prescriptions. The rules exist and they are narrower than the summaries suggest.

Yes — and the honest version is that most of the "it stopped working" posts turn out to be a normal fortnight of water weight.

Had the conversation with a clinician before stopping rather than after. Considerably easier that way round.

Cosigning on cross-border prescriptions. The rules exist and they are narrower than the summaries suggest.

amylin and GLP-1 are not redundant pathways

The translation cost of dealing with a foreign pharmacy was the thing I had not budgeted for.

Asked a pharmacist about the absorption question rather than the internet. Ten minutes, clear answer, done.

STEP-1 averaged just under 15% at 68 weeks, so a 10% year is not a failure

the habits are what has to carry it afterwards

Is this a PCOS diagnosis or an insulin resistance finding?

Has this been raised with whoever prescribes?

Perimenopausal, or is that a separate question?

Adding the one thing nobody warns about — fertility can change, and quickly.

Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.

The national shortage database is a primary source with expected resolution dates attached. It is public, searchable, and consistently more accurate than reporting about it.

Cosigning. The appetite change and the scale change ran about three weeks apart for me too.

Correct, and worth adding: the trial average is an average. Half the people in it did worse than 15% and were still on the drug.

Does fatigue track the day after the shot, or is it there all week?

Careful — interval stretching and dose reduction are different interventions and your post uses them interchangeably.

ferran_krastev is right that regain is a documented outcome rather than a character verdict.

That shortage notice was national and does not apply where the question is coming from.

Disagreeing with this bit: that criterion belongs to one member state and is being quoted as general.

Supply notices are issued nationally. A notice in one member state does not imply availability problems in another, even for the same product.

Assumed the New Zealand position applied here. It does not, and someone corrected me politely with the actual source.

The appetite thing was the surprise. I expected to feel full. What I got was simply not thinking about food between meals.

There is very little published guidance on stopping specifically, which is exactly why board consensus here should carry less weight than usual and a clinician conversation should carry more.

The appetite thing was the surprise. I expected to feel full. What I got was simply not thinking about food between meals.

That reads as advice to stop, which is not something anyone here should be offering.

Right, and symptom patterns tracking the cycle rather than the dose explains a lot of confusing weeks.

Agreed. Appetite is the leading indicator and the scale is the lagging one. Watch the first, not the second.

The same dose genuinely feels different at different points in the month for me. Took a year to notice and it was in the log the whole time.

Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.

reimbursement is national, not European, and that is the whole board

staying at 1.7mg for an extra month is a legitimate plan

This. New Zealand has its own regulator and its own funding decisions and the answers genuinely differ.

This matches me almost exactly, right down to the injection-site soreness showing up on the second day and being gone by the fourth.

Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.

That reads like a titration plan and this board cannot give you one. Somebody who actually knows your history has to.

The escalation schedule in the trials existed to keep people on the drug. It is a tolerability ramp, and it is why the label reads the way it does.